31,330€
0,19%
Echtzeit-Aktienkurs Meridian Bioscience Inc.
Bid:
Ask:
Echtzeit-Chart der Meridian Bioscience Inc. Aktie
Börsenkurse Meridian Bioscience Inc.
Fundamentaldaten der Meridian Bioscience Inc. Aktie
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2022 [USD] | 333,02 Mio. | 54,32 Mio. | 42,46 Mio. | 0,96 | - | 32,74 | 4,12 |
| 2021 [USD] | 317,90 Mio. | 90,45 Mio. | 71,41 Mio. | 1,62 | - | 19,32 | 4,27 |
| 2020 [USD] | 253,67 Mio. | 59,29 Mio. | 46,19 Mio. | 1,07 | - | 29,28 | 5,32 |
| 2019 [USD] | 201,01 Mio. | 31,56 Mio. | 24,38 Mio. | 0,57 | 0,80% | 55,16 | 6,66 |
| 2018 [USD] | 213,57 Mio. | 30,38 Mio. | 23,85 Mio. | 0,56 | 1,60% | 56,15 | 6,22 |
| 2017 [USD] | 200,77 Mio. | 36,43 Mio. | 21,56 Mio. | 0,51 | 1,84% | 61,43 | 6,59 |
| 2016 [USD] | 196,08 Mio. | 50,64 Mio. | 32,23 Mio. | 0,76 | 2,55% | 41,22 | 6,73 |
| 2015 [USD] | 194,83 Mio. | 55,06 Mio. | 35,54 Mio. | 0,85 | 2,55% | 36,86 | 6,73 |
| 2014 [USD] | 188,83 Mio. | 52,11 Mio. | 34,74 Mio. | 0,83 | 2,52% | 37,75 | 6,91 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. |
Profil der Meridian Bioscience Inc. Aktie
Meridian Bioscience is an integrated life science company. The Company is engaged in developing, manufacturing, selling, and distributing clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory, and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in three segments: U.S. Diagnostics, European Diagnostics, and Life Science.